708273-70-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5-methoxymethyl-pyridine is used as a key intermediate in the synthesis of new drugs. Its unique structure allows for the development of pharmaceuticals with potential therapeutic applications, contributing to the advancement of medicine.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-5-methoxymethyl-pyridine is utilized as a precursor in the production of pesticides and herbicides. Its incorporation into these products can enhance their effectiveness in controlling pests and weeds, thereby supporting agricultural productivity.
Used in Academic and Industrial Research:
2-Bromo-5-methoxymethyl-pyridine also serves as a valuable compound in research settings. It is employed as a building block for the synthesis of other organic compounds, facilitating the exploration of new chemical reactions and the discovery of novel molecules with potential applications across various fields.

Upstream product

• 67-56-1 methanol 
• 101990-45-8 2-bromo-5-bromomethylpyridine 
• 124-41-4 sodium methylate 
• 3510-66-5 2-Bromo-5-methylpyridine 

Downstream Products

• 708273-71-6 4-hydroxy-4-[5-(methoxymethyl)pyridin-2-yl]cyclohexanone 

Relevant academic research and scientific papers

TYK-2 INHIBITOR

Disclosed herein is a compound of Formula (I) for inhibiting TYK2 and treating a disease associated with the undesirable tyk-2 activity (tyk-2 related diseases), a method of using the compounds disclosed herein for treating inflammatory or autoimmune disease, and a pharmaceutical composition comprising the same.

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

A METHOD OF TREATING LIVER FIBROSIS

The present invention relates to a method of treating hepatis C and/or liver fibroisis with 3-cycloalkylaminopyrrolidine derivatives of the present invention

3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors

The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.